TCON Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
TRACON Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.053 |
| 52 Week High | US$14.75 |
| 52 Week Low | US$0.002 |
| Beta | 1.36 |
| 11 Month Change | -59.87% |
| 3 Month Change | -64.36% |
| 1 Year Change | -98.18% |
| 33 Year Change | -99.92% |
| 5 Year Change | -99.92% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Tracon Pharmaceuticals announces $35M non-dilutive debt facility
Sep 06Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma
Aug 29Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M
Aug 10TRACON Pharmaceuticals announces $5M registered direct offering
Dec 29TRACON Pharma launches $8.8M direct offering
Dec 22Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study
Dec 10Tracon Pharma files China application for envafolimab in solid tumors
Nov 16Shareholder Returns
| TCON | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -29.8% | -0.7% | -1.6% |
| 1Y | -98.2% | 19.8% | 30.8% |
Return vs Industry: TCON underperformed the US Biotechs industry which returned 19.8% over the past year.
Return vs Market: TCON underperformed the US Market which returned 30.8% over the past year.
Price Volatility
| TCON volatility | |
|---|---|
| TCON Average Weekly Movement | 61.3% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: TCON's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TCON's weekly volatility has increased from 46% to 61% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 17 | Craig Jalbert | www.traconpharma.com |
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company’s clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors.
TRACON Pharmaceuticals, Inc. Fundamentals Summary
| TCON fundamental statistics | |
|---|---|
| Market cap | US$181.79k |
| Earnings (TTM) | US$5.20m |
| Revenue (TTM) | US$3.20m |
0.0x
P/E Ratio0.1x
P/S RatioIs TCON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCON income statement (TTM) | |
|---|---|
| Revenue | US$3.20m |
| Cost of Revenue | US$12.11m |
| Gross Profit | -US$8.91m |
| Other Expenses | -US$14.10m |
| Earnings | US$5.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.52 |
| Gross Margin | -278.31% |
| Net Profit Margin | 162.34% |
| Debt/Equity Ratio | 0% |
How did TCON perform over the long term?
See historical performance and comparison